Effect of nifedipine on alprazolam-induced anxiolysis and brain GABA level changes in albino rates

Suher M. Aburawi, PhD, *Syed S. Ahmed,* MD, *Issa E. Amara,* BSc, *Rida A. Altubuly,* PhD.

ABSTRACT

Objectives: The present study investigates the effects of alprazolam (ALP) and nifedipine alone or in combination on behavior and on -aminobutyric acid (GABA) levels, in discrete brain regions of albino rats.

Methods: The anxiolytic effect was studied using a plus maze model and brain levels of GABA were measured using high performance liquid chromatography. Four acute treatment groups of rats were used. In the first they were treated with 1% Tween 80 (1ml/kg), in the second with nifedipine (10mg/kg), in the third with ALP (2mg/kg) and in the fourth with ALP in addition to nifedipine in the respective doses. The work was carried out at the Faculty of Pharmacy of Al-Fateh University, Tripoli, Libya in the first half of 2002.

Results: The results indicate that the anxiolytic effect of ALP was not modified by nifedipine. Nifedipine by itself significantly decreased the motor activity (decrease in total lines crossed), this effect was apparently antagonized by ALP. Alprazolam administration produced an increase of GABA levels in cerebellum and striatum and a decrease in the brain stem. Nifedipine per-se had no effect on GABA levels in the brain stem but it partially antagonized ALP-induced inhibitory effect on GABA in this region. Alprazolam significantly increased GABA levels in the striatum, while nifedipine alone had no effect on neurotransmitter levels and did not modify the ALP effect in this brain region. Alprazolam or nifedipine had no significant effect on GABA levels in midbrain, cerebral cortex and whole brain. There were no significant changes in GABA levels in midbrain and whole brain with drug combination. However, the combination decreased GABA levels significantly in the cerebral cortex.

Conclusion: It may be concluded that, the anxiolytic effect of ALP possibly occurs through changes in brain GABA levels (an increase in cerebellum and striatum with a decrease in brain stem). The effect was not modified by nifedipine which per se had no affect on GABA levels in any brain area. The significant decrease in GABA levels in cerebral cortex by ALP-nifedipine combination may be due to the mutual closure of calcium channel (mentioned in literature) resulting in inhibition of the EAA-ergic input to GABA-ergic neuron.

Neurosciences 2003; Vol. 8 (2): 96-103

The prominent effects of benzodiazepines - sedation, hypnosis, decreased anxiety, muscle relaxation, anterograde amnesia and anticonvulsant activity, virtually all result from actions of these drugs on the central nervous system (CNS). Alprazolam (ALP), one of the benzodiazepines, also has antidepressant activity in a clinical study.[1-3] The drug is an anti-anxiety agent, used primarily for short-term relief of mild to moderate anxiety.[4-7] It is also effective in the treatment of depression or in panic disorders with or without agoraphobia.[7] The benzodiazepine receptor (BZR) is an allosteric modulatory site within the -aminobutyric acid (GABA)A receptor-chloride channel complex. The nature and distribution of GABA-BZR complex is shown to be essentially similar to human and rat brain.[8,9] Agonists and partial agonists enhance apparent GABA

potency at GABA$_A$ receptors maximally (2-3 fold) or submaximally.[10] It is possible that the dichotomy of the antidepressant effects of ALP[11,12] from the anxiolytic effects may be related to the degree of receptor occupancy or the pharmacokinetic difference amongst 1,4-benzodiazepines.[13,14] The major molecular target for BZ is the inhibitory neurotransmitter (GABA) system[15,16] which affects nearly all of the CNS[17,18] and produces anti-anxiety action.[19,20] Furthermore GABA-mimetics such as muscimol, 4,5,6,7-tetrahydroisoxazolo [4,5-c]pyridine-3-ol (THIP), isoguvacine and aminoacetic acid have been shown to have anti-anxiety effects in social interaction tests[21-23] and in the elevated-plus maze.[24] Alprazolam binds with high affinity to the GABA benzodiazepine receptor complex and its central pharmacological/therapeutic actions are mediated via interaction with this receptor complex.[7] It is well known that GABA receptor stimulation produces opening of chloride (Cl$^-$) channels resulting in hyperpolarization.[25] However GABA is also related to calcium channels as evident from a recent study which mentions that astrocytes accelerate the developmental change in the Cl$^-$ ion gradient extrinsic to GABAA receptor/Cl$^-$ channel, which is critical for triggering calcium (Ca^{2+}) entry, without influencing parallel changes in the intrinsic properties of the channels.[26] It was also found that GABA response shares a common pathway of Ca^{2+} movement with the high potassium (K$^+$) induced response; suggesting that the stimulation with GABA results in Ca^{2+} influx through voltage-gated Ca^{2+} channels, and these effects are dependent on Cl$^-$ transport systems.[27] Furthermore it is substantiated by the study which shows the ability of progesterone, GABA, or muscimol to stimulate acrosomal exocytosis in mouse spermatozoa which was blocked by the Ca^{2+} channel antagonist - nifedipine[28] which, like most channel blockers prevents the opening of voltage gated Ca^{2+} channels [Long lasting (L) and transient (T) types].[25] It has recently been shown that GABA or muscimol have a depolarizing effect on Ca^{2+} channel which is antagonized by nifedipine.[29] It has been explained that the mechanism by which GABA receptor stimulation results in elevated intracellular calcium [Ca^{2+}]i, is due to membrane depolarization by increased Cl$^-$ conductance resulting in calcium influx through L-type voltage-dependent calcium channel in neonatal rat pituitary cells.[30] The experimental work on the effect of ALP on animal behavior is scanty.[31,32] Most of the studies concentrated on the swimming maze model for ALP antidepressant action.[33-36] Clinically, ALP (xanax) may be prescribed with calcium channel blockers which are used as antihypertensive (nifedipine and diltiazem) and anti-angina (nifedipine and diltiazem) remedies. With these relationships of ALP modifying the GABA-receptor complex, the interaction of GABA-receptor with calcium channel and the possibility of concomitant use of ALP with Ca^{+2} channel blockers, the present work was undertaken to evaluate the effect of ALP, as an anxiolytic drug, its effect on GABA levels in different brain regions and possible interaction on behavior and GABA levels when both are administered together.

Methods. -amino-n-valeric acid (valine; 5-aminopentanoic acid); -amino-n-butyric acid (GABA; 4-aminobutanoic acid; Piperidic acid) were obtained from Sigma Chemical Company, United States of America (USA); acetonitrile and methanol chromasol for liquid chromatography from SDS, France; phosphoric acid was obtained from Riedel-De Haen AG Seelze Hanover, Germany; perchloric acid from May & Baker Ltd, England; potassium carbonate and sodium hydrogen carbonate from BDH Limited, England; dansyle chloride (5-dimethylamino naphthalene-1-sulfonyl chloride), anhydrous acetone from Koch-Light Ltd, England, glacial acetic acid from BDH Limited, England and potassium dihydrogen phosphate was obtained from Riedel-De Haen AG, Germany. Alprazolam (ALP) was supplied by Upjohn Company, Egypt; and Tween 80 (T80) from Riedel-De Haen AG, Germany. Nifedipine was supplied by Bayer Company, Germany.

Male albino Wistar rats weighing between 150 and 250 gms were used. Each group was housed separately in a cage, except during the time of measurements. Standard rat food pellet diet and water were available ad lib. The animals were kept at constant room temperature (20-25°C), and 12 hours dark/light cycle. Alprazolam and nifedipine were administered by the intraperitoneal route. A volume of injection of 1.0ml/kg of body weight was adopted.[37] The suspending agent used for ALP was 1%Tween 80 in water.[38]

Acute administration. The rats were divided into 4 equal groups of 6 animals each. Group I the control group received only a single dose of 1% Tween 80 (T80). Group II received a single dose of 2mg/kg ALP. Group III received a single dose of 10mg/kg nifedipine. Group IV received doses of 2mg/kg ALP and 10mg/kg of nifedipine at the same time. Behavioral measurements using elevated plus maze were scored immediately after 30 minutes of drugs administration.[39-41] The levels of GABA in brain were measured at the end of the behavior measurements.

Behavioral measurements. The elevated plus-maze was made of wood with 2 opposite open arms (50 x 10cm) and 2 opposite closed arms of the same size with walls of 40cm height. The arms were connected by a central square (10 x 10cm), thus the maze formed a plus sign. The plus-maze was elevated 50cm above the floor. The plus-maze test was conducted between 9am and 1pm in a closed room with low level of illumination[42] and under constant conditions of temperature, humidity and the natural light-dark cycle. Each rat was placed on the central square of the plus-maze, facing one of the closed arms, and was observed for 4 minutes of free exploration. The numbers of entries into arms, lines crossed and times spent on open and closed arms were

scored. An entry was defined as having both forepaws in the respective arm. Line crossing was defined as both forepaws crossing the line.[43] Anxiety measure (AM) was calculated by dividing the time spent in closed arm by the total time of the test.

Measurements of GABA. Rats were killed by cervical dislocation and decapitation, and the body was exposed to a microwave irradiation for 4 seconds.[44-46] The brains were quickly removed and placed on an ice-cooled glass plate. The cerebellum was removed first by cutting the cerebellar peduncles, followed by the pons and medulla which were separated from the rest of the brain. The cerebral cortex was then pulled away to expose the corpus callosum to expose the lateral ventricles. The striata protruding from the inner surface of the cerebral hemispheres into the ventricles together with the caudate nuclei, were removed by gently scraping the inside of the ventricle with a sharp scalpel. The cerebral hemispheres were then dissected from the rest of the brain.[47,48] The removed brain regions were weighed and were placed in 100 ml plastic tubes previously placed in iced bath and containing 10ml of ice-cooled 0.1M perchloric acid.[44,45] The tissues were homogenized in Fisher Dyna-Mixer (Fisher Scientific, USA) for one minute keeping the tube embedded in an ice bath, and then centrifuged at 5000 rpm for 10 minutes at 4°C. The supernatants were stored at 20°C until assayed. Calibration curves were constructed by carrying solutions of standard GABA (25, 50, 100, 200 and 300 μg/ml) in 1.0ml perchloric acid, each containing 150μg/ml of valine as an internal standard. One milliliter of each standard solution was diluted to 10ml with perchloric acid. Dansylation was carried out by taking 100μl of the supernatant of the samples or the standards and added to a micro-tube containing 100μl of 0.1M potassium carbonate solution. The solutions were mixed using vortex mixer and then centrifuged using microcentrifuge at 10.000 rpm for 10 minutes. A 100μl of the supernatant of the centrifuged mixture was transferred into a pyrex tube containing 100μl of 0.1M sodium hydrogen carbonate solution, and then adding 400μl of working dansyl chloride solution. The tubes were shaken for 30 seconds using vortex mixer and then incubated at 90°C in benchtop oven for 30 minutes. The tubes were not capped during the incubations, so as to allow much of the sample to evaporate during incubation. This did not appear to adversely affect the progress of the dansylation reaction and served to concentrate the samples. After removal from the oven, the tubes were left to cool down to room temperature, and the dansylated derivatives were transferred into 1.5ml microtubes and stored at 20°C until assayed.[46] The high performance liquid chromatography (HPLC) system used to resolve and quantify the samples,[45] consisted of an LKB system from LKB-Produkter AB, Bromma, Sweden. It is formed of solvent conditioner (2156 LKB Bromma), column oven (2155 LKB Bromma), pump (2150 LKB Bromma), and recording integrator (2220 LKB Bromma). The HPLC columns were 5mm, 250 x 3.2mm, C8 reversed -phase column

from Phenomenex, St. Torrance, CA90501 USA. The flourometric detector was made by Phillips (Japan). The HPLC mobile phase[46,48] consisted of helium degassed deionized water-acetonitrile (HPLC grade) mixture (65:35, v/v) containing 0.15% (v/v) phosphoric acid. The flow rate was kept at 0.5 ml/min. The detector excitation was at 333nm and emission at 532nm. Twenty-five microliters of the dansyl derivative of GABA sample was transferred to HPLC microsample vials and injected into the column. The peak ratios of the samples were calculated with reference to the internal standard. The concentration of the samples was calculated from concentration-peak ratio curve of dansylated standards. Linear regression and sample concentration was calculated using windows 3.1 (Excel) software package. Retention time of GABA and internal standard were found to be in the range of 4.96, and 5.85 minutes.

Statistical analysis. Descriptive statistical analysis was applied on parameters of different samples using Statistical Package for Social Sciences version 8 to find out whether the observed samples were normally distributed using Kolmogorov-Smirnov maximum deviation test for goodness of fit. If the parameters were normally distributed, treatments were compared in pair-wise fashion by applying one way ANOVA. If the parameters were not normally distributed, the treatments were compared by applying the Mann-Whitney 2 samples (non-matched) test. The differences were considered to be significant at P<0.05.

The work was carried out at the Faculty of Pharmacy of Al-Fateh University, Tripoli, Libya in the first half of 2002.

Results. The behavioral results using the plus maze are shown in **Table 1**. Acute administration of ALP produced a significant increase in time spent in open and zero areas, compared to the effect of acute 1% Tween 80 (control group). Alprazolam also significantly decreased the time spent in closed areas. Administration of nifedipine significantly antagonized the effect of ALP in open areas, and insignificantly in closed and zero areas. The anxiety measure was decreased significantly by ALP compared to control (T80 treated group), this decrease was insignificantly antagonized by nifedipine although the anxiety measure remained less significantly than the control. The numbers of entries into the open areas increased after the administration of ALP; this effect was abolished by nifedipine administration when compared to the control. The number of entries into the closed areas and the total number of entries (into the closed and the open areas) were not changed by any of the different treatments. The effect of acute administration of drugs (ALP and nifedipine) on spontaneous motor activity was studied with respect to the total number of lines crossed in all areas and in different individual areas. Alprazolam neither changed the number of lines crossed in closed areas nor the total lines crossed. Nifedipine however

showed significant decrease in the total lines crossed; the effect was abolished by ALP compared to the control. The results and the statistical analysis for the changes in GABA concentrations in different brain areas are given in **Table 2**. The acute administration of ALP (2mg/kg) increased the levels of GABA significantly in the cerebellum. Nifedipine per se had no effect on cerebellum GABA levels and it also failed to antagonize alprazolam effect in this region. In brain stem, ALP decreased GABA levels significantly. Commitment administration of nifedipine apparently abolished the inhibitory effect of ALP. Nifedipine administration alone had no effect on GABA levels. The levels of GABA were highly increased in striatum after administration of ALP; this increase was not affected by nifedipine when administered with ALP. Nifedipine by itself had no effect on GABA levels in striatum. Alprazolam had no significant effect on midbrain GABA levels. Nifedipine neither had any effect on GABA levels nor it modified the effect of ALP. In cerebral cortex, both nifedipine and ALP administered alone had no effect on GABA levels, but in combination, GABA levels were significantly decreased compared to the control. In the whole brain, there was no change in GABA levels by any of the treatments.

Discussion. Using plus maze model, acute ALP administration produced a significant decrease in anxiety measure (**Table 1**). Alprazolam treated rats spent more time in open and zero areas, less in closed areas and increased the number of entries into open arms, compared to the control (T80 treated groups). It should be mentioned that time spent and number of entries into open arms are negatively related to anxiety, while the time spent on the closed arms is positively related.[49] This agrees well with our results. The anxiolytic action of BZ is due to the binding to benzodiazepine receptor subtype1 (BZR1) which results in the anxiolytic non-sedative action[50] activating BZ-GABA-chloride channel complex.[51,52] Different parameters were reported in the literature to measure anxiolytic effect and motor activity in the elevated plus maze. These parameters include: lines crossed in open, closed and in all areas; time spent in open, closed and in all areas; number of entries into open, closed and into all areas. The relationship of these parameters to anxiety and motor activity was studied by Cruz and his colleagues[49] in rats left on elevated plus maze for 5 minutes. They mentioned 2 independent factors emerged from a factor analysis. The variables that loaded highly and negatively on factor one (seemingly related with anxiety) were: number of entries and time spent in open areas, percentage of open/total areas entries and percentage of time on open areas/total time of the test. The time spent on closed areas loaded highly, but positively on factor one. On the other hand, number of the closed arms entries, total number of arms entries and rearing loaded highly on factor 2 (probably related to motor activity). However, the total number of entries also loaded on factor one, being thus a mixed index. Similarly, the number of open arm entries loaded on both factors one and 2. Based on this, it is concluded that, ALP has an anxiolytic action (increase time spent in open and zero areas; decrease time spent in closed areas - lines and number of entries into open areas was increased) without any sedative effect (total lines crossed and total entries was not changed).

Nifedipine alone in the dose used (10mg/kg) did not change the time spent in any areas. Most of the known calcium antagonists act preferentially or solely on the L channel[53,54] which has no significant depressant effects on CNS.[55] However, it is known that the calcium entry that triggers neurotransmitters release through the N channels.[25] Nifedipine did not change the anxiolytic effect of ALP, since it has no effect on the calcium entry mechanism that triggers neurotransmitter release related to anxiolytic action. Nifedipine by itself decreased the motor activity (decreased the total lines crossed), this may be due to block of calcium channel at motor neurons which may produce muscle relaxation (unpublished results), leading to decreased motor activity (**Table 1**). Nifedipine-induced decrease in motor activity was apparently antagonized by ALP; this may be due to the anxiolytic action that may increase the animal exploratory behavior, resulting in increase in lines crossed.[56,57] It is therefore concluded that ALP produces anxiolysis and this action is not changed by the administration of nifedipine.

In the present investigation, an attempt has been made to correlate behavioral effects of drugs with brain GABA level. Acute administration of ALP produced significant increase in GABA levels in cerebellum and striatum (**Table 2**). This increase might be due to increase GABA synthesis through the stimulation of glutamate decarboxylation.[58] Thus the therapeutic effects of BZ (sedation, hypnosis or antianxiety) might be due to the increase in GABA levels in the brain regions (cerebellum, cerebral cortex, the limbic system and reticular formation) where the BZ binding sites are present.[59] The main brain regions for the presence of BZ1 receptor subtype are cerebellum, inferior colliculus, globus pallidus and substantia nigra pars reticularis.[60] This facet of BZ action may be one apart from the well known mechanism through the full selective allosteric modulation maximizing GABA action.[61,62] The modulator allosteric site on GABA-chloride channel complex mediates both facilitatory (BZ-receptor agonists) and inhibitory (inverse agonists) effects.[63] The other mechanisms that may contribute to anxiolytic effect involve neither GABA nor alterations in membrane permeability to chloride ion, and include inhibition of uptake of adenosine and potentiation of endogenous neuronal depressant adenosine,[64] GABA-independent inhibition of Ca^{+2} current,[65,66] Ca^{2+}-dependent release of neurotransmitters[25] and inhibition of tetrodotoxin sensitive Na^+ channel.[67] It is also possible that the action of ALP on GABA may be through the endogenous neurosteroids since it has been

Table 1 - Effect of alprazolam alone and in combination with nifedipine on behavior using the plus maze.

Treatments	Time spent in different areas				Number of entries into different areas			Lines crossed in different areas		
	Open	Closed	Zero	AM	Open	Closed	Total	Open	Closed	Total
1%T80 (1ml/kg)	0.0	239.17±0.307	0.833±0.307	0.997±0.0012	0.0	1.17±0.166	1.17±0.166	0.0	9.33±1.173	**9.33±1.173**
Nifedipine (10mg/kg)	2.57±2.57	212.71±14.54	24.71±12.546	0.886±0.061	0.143±0.143	1.29±0.285	1.43±0.429	0.285±0.285	5.43±1.586 *	**5.71±1.847** *
Alprazolam (2mg/kg)	43.5±38.97 *	146.83±37.45 *	49.67±25.914 *	0.612±0.156 *	0.67±0.333 *	1.83±0.703	2.5±0.847	1.16±0.654 *	9.50±4.794	**10.66±5.064**
Alprazolam +nifedipine	24±24	196.83±24.69 *	19.02±8.592 *	0.820±0.103 *	1.0±1.0	2.33±0.714	3.33±1.476	4.16±4.16	11.17±4.672	**15.33±7.783**

The values are the means ± SE for 6 rats
AM - Anxiety measures (time spent in closed areas/total of the test)
*Significantly different from T80 treated group at $p<0.05$

Table 2 - Effect of alprazolam alone and in combination with nifedipine on GABA levels in different brain areas.

Treatments	Cerebellum	Brain stem	Striatum	Midbrain	Cerebral cortex	Whole brain
1%T80 (1ml/kg)	184.44±10.741	170.85±10.259	405.93±37.830	245.40±8.499	174.85±8.906	212.56±16.46
Nifedipine (10mg/kg)	202.02±3.549	148.33±7.374	393.96±25.087	248.45±11.794	169.26±9.194	227.65±10.105
Alprazolam (2mg/kg)	284.98±28.473 *	127.35±10.424 *	996.63±57.228 *	285.17±22.436	152.89±19.702	221.29±10.027
Alprazolam +nifedipine	262.86±10.177 *,†	158.79±7.364	831.62±82.065 *,†	278.70±21.525	134.66±9.378 *,†	215.90±12.312

The values are the means ± SE for 6 rates
* Significantly different from the T80 treated group (control) at $p<0.05$
† Significantly different from nifedipine treated group at $p<0.05$


Figure 1 - GABA - EAA interrelationship in the central nervous system. GABA - -aminobutyric acid. EAA- excitatory amino acid.

shown that, mitochondrial and glial BZ receptors[68] increase neurosteroidal biosynthesis. Furthermore, the neurosteroids stimulate GABA and its neurotransmitter mechanisms[69-71] and may be related to anxiolysis.[72-74]

The increase in GABA levels by ALP was observed only in cerebellum and striatum, probably ALP dose may not be enough to produce action in other areas. Cerebellum is known to be involved in emotional cognitive processes and anxiolysis.[75] On the other hand, striatum has a key position to serve as an integrating unit modulating cerebral cortex, thalamus and the limbic system functions.[76-78] Striatum is previously shown to have maximum GABA level increase by low doses of triazolam[48] and it is also very sensitive to acute stress where GABA levels, in rat corpus striatum, were reduced by acute immobilization stress.[79]

Administration of ALP alone produced a significant decrease in brain stem GABA levels. It may interact with a low affinity site that results in negative allosteric action thus inhibiting GABA currents.[80,81] This effect may be through direct inhibition of the influx of extracellular Ca^{+2},[82] or reduction of the transient currents through type one calcium channel.[65] Nifedipine administration by itself had no effect on GABA levels in any of the brain areas, although it showed an insignificant decrease in brain stem. It is possible that intracellular calcium entry through nifedipine-sensitive calcium channels may have no effect on GABA release. Alternatively nifedipine dose may not be enough to produce any changes in brain GABA levels.

Calcium plays an important role in post synaptic membrane function and in neurotransmitter secretion from presynaptic terminals.[83] The calcium channels in CNS have different structural and functional characteristics.[84] It is becoming increasingly apparent that multiple receptors systems of different neurotransmitters in brain produce their responses by indirectly altering calcium channel activity (for example, altering membrane potential or threshold) without directly affecting the channel itself.[85] Voltage sensitive calcium channels have different protein structures which provide considerable latitude for the development of drugs with specific effects on these calcium channel receptor subtypes in the CNS.[85] Nifedipine in this study failed to antagonize ALP effect on GABA in cerebellum and striatum. Therefore it is possible that nifedipine exclusively acting on L-type calcium channel and not on N-type which is responsible for neurotransmitter release.[25,55] In cerebellum and striatum, GABA synthesis or secretion, may be controlled by calcium released from the sarcoplasmic reticulum[86,87] and not affecting calcium entry through the channel which is not antagonized by calcium antagonists.[25] The dihydropyridines affect Ca^{+2} channel function in a complex way, not simply by a physical plugging of the pore but binding to the same site acting in the converse way, namely promoting the opening of voltage-gated calcium channels.[88] Nifedipine apparently abolished the ALP-induced decrease in GABA levels in brain stem. Nifedipine may act in converse way (vide supra); the entry of extracellular Ca^{+2} can trigger the release of additional Ca^{+2} from the intracellular stores[55] which may lead to the release of neurotransmitter (GABA), as a result of this mechanism nifedipine may antagonize the ALP induced decrease in GABA levels in brain stem.

Benzodiazepines are shown to increase GABA levels in cerebral cortex.[48] However in the present investigation ALP did not produce any significant changes. Nifedipine also did not change GABA levels in cerebral cortex. However the administration of nifedipine and ALP together produced a decrease in GABA levels. It is possible that ALP-induced increase in striatal GABA levels cause inhibition of excitatory neurons going to the cerebral cortex.[89] This effect may be through blocking[90] or reducing the transient (T-type or type I) and long lasting (L-type or type II) type of calcium channel currents.[65] Nifedipine when given with ALP, there will be summation of effects on calcium channel causing its closure (**Figure 1**).

Therefore it may concluded that ALP in the dose used produced anxiolytic non-sedative action. It increased GABA levels in cerebellum and striatum which may be related to the anxiolytic effect. Alprazolam decreased GABA levels in brain stem, which was abolished by nifedipine. Nifedipine alone had no effect on anxiety measure, but decreased motor activity which was abolished by ALP. Nifedipine alone did not change GABA in cerebral cortex, but combination with alprazolam produced a significant decrease in GABA levels. It seems that calcium channel is complexly related to GABA in different brain regions in different directions.

References

1. Rall TW. Hypnotic and sedatives; ethanol. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. Good and Gilman's. The pharmacological basis of therapeutics. 8th ed. Singapore City (SG): Maxwell Macmillan Singapore Pte Ltd; 1991. p. 345.
2. Zarcone VP Jr, Benson KL, Greene KA, Csemansky JG, Faull KF. The effect of chronic alprazolam on sleep and bioamine metabolites in depression. *J Clin Psychopharmacol* 1994; 14: 36-40.
3. Jonas JM, Hearron AE Jr. Alprazolam and suicidal ideation: a meta-analysis of controlled trials in the treatment of depression [see comments *J Clin Psychopharmacol* 1997; 17: 328; discussion 329]. *J Clin Psychopharmacol* 1996; 16: 208-211.
4. Enkelmann A. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. *Psychopharmacology (Berl)* 1991; 105: 428-432.
5. Prunell M, Escorihuela RM, Femandez-Teruel A, Nunez JF, Tobena A. Anxiolytic profiles of alprazolam and ethanol in the elevated plus-maze test and the early acquisition of shuttlebox avoidance. *Pharmacology Research* 1994; 29: 37-46.
6. Woodman CL, Noyes R Jr, Ballenger JC, Lydiard RB, Sievers G, Mihalko D. Predictors of response to alprazolam and placebo in patients with panic disorder. *J Affect Disord* 1994; 30: 5-13.
7. Phillip W, Long MD. Drug monograph, alprazolam. Internet Mental Health 1999. Available from: URL: http://www.mentalhealth.com
8. Reisine TD, Wastck GL, Speth RC, Bird ED, Yamamura HI. Alteration in the benzodiazepines receptor of Huntington's disease in human brain. *Brain Res* 1979; 165: 183-187.
9. Schoch P, Richards TG, Haring P, Jakaes B, Stahli C, Staehelin T et al. Co-localization of GABAA receptors and benzodiazepine receptors in the brain shown by monoclonal antibodies. *Nature* 1985; 314: 168-171.

10. Haefely W. The GABA-Benzodiazepine interaction fifteen years later. *Neurochem Res* 1990; 15: 169-174.

11. Feighner JP. Comparative trials of alprazolam and tricyclic antidepressants in the management of depressive states. In: Lader MH, Davies HCD, editors. Drug Treatment of Neurotic Disorders: Focus on Alprazolam. Edinbrugh (UK): Churchill Livingstone; 1985. p. 116-128.

12. Laakmann G, Hinz A, Neuhauser H. New neuroendocrine aspects of depression and anxiety. *Clin Neuropharmacol* 1986; 4: 245-247.

13. Haefely W, Pieri L, Schaffner R. General pharmacology and neuropharmacology of benzodiazepine derivatives. In: Hoffmeister F, Stille G, editors. Handbook of Experimental pharmacology, Berlin (DE): Springer Verlag; 1981. p. 13-262.

14. Peterson EN, Jensen LH, Orejer LH, Honore J. New perspectives in benzodiazepine receptor pharmacology. *Pharmacopsychiatry* 1986; 19: 4-6.

15. Haefely W, Kyburz E, Gerecke M, Mohler H. Recent advances in the molecular pharmacology of benzodiazepine receptors and the structure-activity relationships of their agonists and antagonists. In: Testa B, editor. Advances in Drug Research. London (UK): Academic Press; 1965. p. 165-332.

16. Olsen RW, Tobin AJ. Molecular biology of GABAA receptors. *FASEB J* 1990; 4: 1469-1480.

17. Leonard BE. Neurochemistry: modulation of GABAergic function by benzodiazepines. In: Hindmarch I, Beaumont G, Brandon S, Leonard BE, editors. Benzodiazepines: Current concepts. Chichester (UK): John Wiley and Sons Ltd; 1990. p. 43-60.

18. Malcangio M, Gowery NG. GABA and its receptors in the spinal cord. *Trends Pharmacol Sci* 1996; 17: 457-462.

19. Stein L, Belluzzi JD, Wise CD. Benzodiazepines: behavioral mechanisms. *Am J Psychiatr* 1977; 134: 665-669.

20. Billingsley ML, Kubena RK. The effects of naloxone and picrotoxin on the sedative and anticonflict effects of benzodiazepines. *Life Sci* 1978; 22: 897-906.

21. File SE. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. *J Neurosci Methods* 1980; 2: 219-238.

22. Gardner C, Guy Y. A social interaction model of anxiety sensitive to actually administered benzodiazepines. *Drug Dev Res* 1984; 4: 207-214.

23. Corbett R, Fielding S, Cornfeldt M, Dunn RW. GABA mimetic agents display anxiolytic-like effects in the social interaction and elevated plus maze producers. *Psychopharmacology* 1991; 104: 312-316.

24. Pellow S, File S. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. *Pharmacol Biochem Behav* 1986; 24: 525-529.

25. Rang PH, Dale MM, Ritter JM. Pharmacology. 3rd ed. London (UK): Churchill Livingstone Publishers 1995. p. 269 and 491.

26. Li YX, Schaffner AE, Walton MK, Barker JL. Astrocytes regulate developmental changes in the chloride ion gradient of embryonic rat ventral spinal cord neurons in culture. *J Physiol (Lond)* 1998; 509: 847-858.

27. Takebayashi M, Kagaya A, Hayashi T, Motohashi N, Yamawaki S. Gama-Aminobutyric acid increase intracellular Ca2+ concentration in cultured cortical neurons: role of CL-transport. *Eur J Pharmacol* 1996; 709: 137-143.

28. Shi QX, Roldan ER. Evidence that a GABAA-Like receptor is involved in progesterone-induced acrosomal exocytosis in mouse spermatozoa. *Biol Reprod* 1995; 52: 373-381.

29. Spergel DJ, Krsmanovic LZ, Stojilkovic SS, Catt KJ. L-type Ca2+ channels mediate joint modulation by gamma-aminobutyric acid and glutamate of [Ca2+] and neuropeptide secretion in immortalized gonadodropin-releasing hormone neurons. *Neuroendocrinology* 1995; 61: 499-508.

30. Horvath G, Acs Z, Mergl Z, Nagy I, Markara GB. Gamma-aminobutyric acid-induced elevation of intracellularcalcium concentration in pituitary cells of neonatal rats. *Neuroendocrinology* 1993; 57: 1028-1034.

31. Kalin NH, Shelton SE, Tumer JG. Effects of alprazolam on fear-related behavioral, hormonal, and catecholamine responses in infant rhesus monkeys. *Life Sci* 1991; 49: 2031-2044.

32. Kelly JP, Wrynn AS, Leonard BE. Olfactory bulbectomized rat as a model of depression: an update. *Pharmacolol Ther* 1997; 74: 299-316.

33. Abel EL, Hannigan JH. The immobility response in the forced swim test: paradoxical effect of imipramine. *Eur J Pharmacol* 1994; 258: 261-264.

34. Pal SN, Dandiya PC. Glutathione as a cerebral substrate in depressive behavior. *Pharmacol Biochem Behav* 1994; 48: 845-851.

35. Sabatino M, Cannizzaro C, Flugy A, Gagliand M, Mineo A, Cannizzaro G. NMDA-GABA interactions in an animal model of behaviour: a gating mechanism from motivation toward psychotic-like symptoms. *Eur Neuropsychopharmacol* 1994; 4: 103-109.

36. Hata T, Itoh E, Nishikawa H. Behavioral characteristics of SART-stressed mice in the forced swim test and drug action. *Pharmacol Biochem Behav* 1995; 51: 849-853.

37. Assandri A, Bernareggi A, Barone D, Odasso G. Pharmacokinetics of premazepam, new anti-anxiety pyrrolodiazepine, in the rat and the dog. *Drugs Exp Clin Res* 1984; X: 241-251.

38. Collinge J, PycocK CJ, Taberner PV. Studies on the interaction between cerebral 5- hydroxytryptamine and -aminobutyric acid in the mode of action of DZ in the rat. *Br J Pharmacol* 1983; 79: 637-643.

39. Lau CE, Wang J. Alprazolam, caffeine and their interaction: relating DRL performance to pharmacokinetics. *Psychopharmacology (Berl)* 1996; 126: 115-124.

40. Coda BA, Mackie A, Hill HF. Influence of alprazolam on opioid analgesia and side effects during steady-state morphine infusions. *Pain* 1992; 50: 309-316.

41. Scavone JM, Greenblatt DJ, Goddard JE, Friedman H, Harmatz JS, Hader RI. The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state. *Eur J Clin Pharmacol* 1992; 42: 439-443.

42. Taylor SC, Johnston AL, Wilks LJ, Nicholass JM, File SE, Little HJ. Kindling with the -Carboline FG7142 suggests separation between changes in seizure threshold and anxiety-related behaviour. *Neuropsychobiology* 1988; 19: 195-201.

43. File SE, Zangrossi H. 'One-trial tolerance' to the anxiolytic actions of benzodiazepines in the elevated plus-maze, or the development of a phobic state? *Psychopharmacology* 1993; 110: 240-244.

44. Schmid R, Karobath M. Specific and sensitive method for the determination of -aminobutyric acid using gas chromatography with electron-capture or mass fragmentographic detection. *J Chromatogr* 1977; 139: 101-109.

45. Zecca L, Zambotti F, Zonta N, Mantegazza P. Determination of -aminobutyric acid in brain areas by high-performance liquid chromatography of dansyl derivatives with ultraviolet detection. *J Chromatogr* 1982; 238: 307-312.

46. Saller CF, Czupryna MJ. -Aminobutyric acid, glutamic, glycine and taurine analysis using reversed-phase high-performance liquid chromatography and ultraviolet detection of dansyl chloride derivatives. *J Chromatogr* 1989; 487: 167-172.

47. Elhwuegi AS. Neurochemical studies into the mode of action of anticonvulsant drugs. [Ph.D. thesis]. Nottingham (UK) University of Nottingham; 1981.

48. Aburawi SM, Elhwuegi AS, Ahmed SS, Saad SF, Attia AS. Effects of acute and chronic triazolam treatments on brain GABA levels in albino rats. *Acta Neurobiol Exp* 2000; 60: 447-455.

49. Cruz AP, Frei F, Graeff FG. Ethopharmacological analysis of rat behavior on the elevated plus-maze. *Pharmacol Biochem Behav* 1994; 49: 171-176.

50. Doble A, Martin IL. Multiple benzodiazepine receptors: no reason for anxiety. *Trends Pharmacol Sci* 1992; 13: 76-81.

51. Primus RJ, Kellogg CK. Experience influnces environmental modulation of function at the benzodiazepine (BDZ)/GABA receptor chloride channel complex. ***Brain Res*** 1991; 545: 257-264.

52. Fernandez-Teruel A, Escorihuela RM, Tobena A, Driscoll P. Stress and putative endogenous ligands of benzodiazepine receptors: The importance of characteristics of the aversive situation and of differential emotionality in experimental animals. ***Experientia*** 1991; 47: 1051-1056.

53. Scharf MB, Fletcher K, Graham JP. Comparative amnestic effects of benzodiazepine hypnotic agents. ***J Clin Psychiatr*** 1988; 49: 134-137.

54. Tsien RW, Fox AP, Hess P, McCleskey EW, Nilius B, Nowycky M, Rosenberg RL. Multiple types of calcium channel in excitable cells. ***Soc Gen Physiol Ser*** 1987; 41: 167-187.

55. Murad F. Drugs used for the treatment of angina: organic nitrate, calcium-channel blockers, and -adrenergic antagonists. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman's the pharmacological basis of therapeutics. Republic of Singapore: Pergamon Press; 1991. p. 774-780.

56. Dawson GR, Tricklebank MD. Use of the elevated plus maze in the search for novel anxiolytic agents. ***Trends Pharmacol Sci*** 1995; 16: 33-36.

57. Dawson GR, Tricklebank MD, Iversen SD, Collinson N, Crawford SP. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. ***Psychopharmacology*** 1995; 118: 316-323.

58. Saad SF, Fahim AT, Attia AS, Seif El-Nasr M. Changes in mouse brain -aminobutyrate metabolism during lorazepam induced abstinence syndromes. ***Med Sci Res*** 1995; 23: 465-467.

59. Potokar J, Nutt DJ. Anxiolytic potential of benzodiazepines receptor partial agonists. ***Central Nervous System Drugs*** 1994; 1: 305-315.

60. Piercey MF, Hoffmann WE, Cooper M. The hypnotics triazolam and zolpidem have identical metabolic effects throughout the brain: implication for benzodiazepine receptor subtypes. ***Brain Res*** 1991; 554: 244-252.

61. Costa E, Guidotti A. Benzodiazepines on trial: a research strategy for their rehabilitation. ***Trends Pharmacol Sci*** 1996; 17: 192-199.

62. Giusti P, Ducic I, Puia G, Arban R, Walser A, Guidotti A, et al. Imidazenil: a new partial positive allosteric modulator of gamma-aminobutyric acid (GABA) action at GABAA receptors. ***J Pharmacol Exp Ther*** 1993; 266: 1018-1028.

63. Haefely W. The GABAA-benzodiazepine receptor: biology and pharmacology. In: Burrows GD, Roth M, Noyes R Jr, editors. Handbook of anxiety: The neurobiology of anxiety. Amsterdan (NL): Elsevier Science Publishers BV (Biomedical Division): 1990a.

64. Phillips JW, O'Regan MH. The role of adenosine in the central actions of the benzodiazepines. ***Neuropsychpharmacol Biol Psychiatry*** 1988; 12: 389-404.

65. Watabe S, Yoshii M, Ogata N, Tsunoo A, Narahashi T. Differential inhibition of transient and long-lasting calcium channel currents by benzodiazepines in neuroblastoma cells. ***Brain Res*** 1993; 606: 244-250.

66. Yoshimura H, Kai T, Nishimura J, Kobayashi S, Takahashi S, Kanaide H. Effects of midazolam on intracellular Ca2+ and tension in airway smooth muscles. ***Anesthesiology*** 1995; 83: 1009-1020.

67. MacDonald RL, McLean MJ. Anticonvulsant drugs: Mechanisms of action. ***Adv Neurol*** 1986; 44: 713-735.

68. Krueger KE, Papadopoulos V. Mitochondrial benzodiazepine receptors and steroid biosynthesis. ***Annu Rev Pharmacol Toxicol*** 1992; 32: 211-237.

69. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. ***Science*** 1986; 232: 1004-1007.

70. Morrow AL, Pace JR, Purdy RH, Paul SM. Characterization of steroid interactions with -amicobutyric acid receptor-gated chloride ion channels: Evidence for multiple steroid recognition sites. ***Mol Pharmacol*** 1990; 37: 263-270.

71. Puia G, Santi MR, Vicini S, Pritchett DB, Purdy RH. Neurosteroids act on recombinant human GABAA receptors. ***Neuron*** 1990; 4: 759-765.

72. Wieland S, Belluzzi J, Hawkinson JE, Hogenkamp D, Upasani R, Stein L, et al. Anxiolytic and anticonvulsant activity of a synthetic neuroactive steroid Co 3-0593. ***Psychopharmacology (Berl)*** 1997; 134: 46-54.

73. Reddy DS, Kulkarni SK. Neurosteroid coadministration prevents development of tolerance and augments recovery from benzodiazepine withdrawal anxiety and hyperactivity in mice. ***Methods Find Exp Clin Pharmacol*** 1997; 19: 395-405.

74. Rodgers RJ, Johnson NJ. Behaviorally selective effects of neuroactive steroids on plus-maze anxiety in mice. ***Pharmacol Biochem Behav*** 1998; 59: 221-232.

75. Nutt DJ. Benzodiazepine dependence: New insights from basic research. In: Hindmarch I, Beaumont G, Brandon S, Leonard BE, editors. Benzodiazepines: Current Concepts, Biological, Clinical and Social Perspectives. England: John Wiley and Sons Ltd; 1990. p. 19-42.

76. Lovell RA, Elliott SJ, Elliott KAC. The -aminobutyric acid and factor I content of brain. ***J Neurochem*** 1963; 10: 479-488.

77. Minard FN, Mushawar IK. Synthesis of -aminobutyric acid from a pool of glutamic acid in brain after decapitation. ***Life Sci*** 1966; 5: 1409-1413.

78. Shank RP, Aprison MH. Post mortem changes in the content and specific radioactivity of several amino acids in four areas of the rat brain. ***J Neurobiol*** 1971; 2: 145-151.

79. Otero Losada ME. Changes in central GABAergic function following acute and repeated stress. ***Br J Pharmacol*** 1988; 93: 483-490.

80. Im HK, Im B, Pregenzer JF, Carter DB, Jacobsen EJ, Hamilton BJ. Characterization of U-97775 as a GABAA receptor ligand of dual functionality in cloned rat GABAA receptor subtypes. ***Br J Pharmacol*** 1995; 115: 19-24.

81. Im HK, Im WB, Von-voigtlander PF, Carter DB, Murray BH, Jacobsen EJ. Characterization of U-101017 as a GABAA receptor ligand of dual functionality. ***Brain Res*** 1996; 714: 165-168.

82. Haugh-Scheidt L, Malchow RP, Ripps H. GABA transport and calcium dynamics in horizontal cells from the skate retina. ***J Physiol Lond*** 1995; 488: 565-576.

83. Jarvis RA, Triggle DJ. Drugs acting on calcium channels. In: Calcium antagonists; their function, pharmacology and clinical relevance. Boca Raton (FL): CRC Press: 1991. p. 197-249.

84. Kennedy MB. Regulation of neuronal function by calcium. ***Trends Neurosci*** 1989; 12: 417-424.

85. Miller RJ. Voltage-sensitive Ca2+ channels. ***J Biol Chem*** 1992; 267: 1403-1406.

86. Zhao Z, Hertz L, Code WE. Effects of benzodiazepines on potassium-induced increase in free cytosolic calcium concentration in astrocytes: interactions with nifedipine and the peripheral-type benzodiazepine antagonist PK 11195. ***Can J Physiol Pharmacol*** 1996; 74: 273-277.

87. Lamacz M, Tonon MC, Smih-Rouet F, Patte C, Gasque P, Fontaine M. The endogenous benzodiazepine receptor ligand ODN increases cytosolic calcium in cultured rat astrocytes. ***Brain Res Mol Brain Res*** 1998; 1-2: 290-296.

88. Schramm M, Thomas G, Towart R, Frankowiak G. Novel dihydropyridines with positive inotropic action through activation of Ca2+ -channels. ***Nature*** 1983; 303: 535-537.

89. Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AF, editors. Goodman Gliman's the pharmacological basis of Therapeutics. New York (NY): McGraw-Hill; 1996; 503-519.

90. Reuveny E, Twombly DA, Narahashi T. Chlordiazepoxide block of two types of calcium channels in neuroblastoma cells. ***J Pharmacol Exp Ther*** 1995; 3522-3565.